logo
Share SHARE
FONT-SIZE Plus   Neg

Enanta Enters Into Strategic Collaboration With Novartis For EDP-239

Private Equity Holding AG or PEH announced that a portfolio company Enanta Pharmaceuticals has entered into a strategic collaboration with Novartis AG (NVS: Quote) for the worldwide development, manufacture and commercialization of its lead development candidate, EDP-239, from its NS5A hepatitis C virus or HCV inhibitor program.

PEH is a minority shareholder and invested in Enanta in 1999 as part of the original shareholder syndicate.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Electronic Arts Inc. (EA) on Tuesday reported an increase in profit for the fourth quarter, reflecting continued strong demand from gamers for titles compatible with new-gen consoles and better digital revenues, with both earnings and revenues topping Wall Street estimates. Redwood City, California-based... Daily deals site Groupon Inc said Tuesday after the markets closed that its first quarter loss narrowed from last year, as revenue increased and operating expenses fell. The company's quarterly earnings per share, excluding item, also came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Mylan reported a plunge in profit, hurt by acquisition costs and a stronger dollar. However, quarterly earnings topped Wall Street estimates, while sales missed expectations despite growth across all regions.
comments powered by Disqus
Follow RTT